Egyptian experience of reliability of 4T's score in diagnosis of heparin induced thrombocytopenia syndrome To evaluate the utility of the 4Ts clinical scoring system as a pretest probability method for detection of heparin-induced thrombocytopenia (HIT). Medical and surgical inpatients and outpatients at Kasr El Eini hospital. This single-centre series of 50 HIT testing referrals assessed combination of clinical score (thrombocytopenia, timing, thrombosis, other causes of thrombocytopenia not evident; 4T's), Heparin platelet factor 4 (H-PF4) rapid particle gel immunoassay (PaGIA) and 14C serotonin release assay (SRA) to develop a practical and well tolerated diagnostic strategy for HIT. Sixteen patients (32%) had a low 4T's score, 26 (52%) had an intermediate score and only eight (16%) had a high score. A positive H-PF4 by PaGIA was seen in seven patients (14%). As might be anticipated, the likelihood of obtaining a positive H-PF4 by PaGIA increased with an increasing clinical score, with positive H-PF4 by PaGIA results in low, intermediate and high scoring patients of 6.25, 7.7 and 50%, respectively. The positive predictive value of a positive PaGIA was 92%. The negative predictive value was 100%. Five patients (10%) in our cohort had a positive SRA. All patients with a positive SRA were included in the intermediate (two of 26 patients, 7.7%) or high (three of eight patients, 37.5%) score groups. The negative predictive value of a low 4T's score was 100%, effectively ruling out HIT. A low 4Ts score supports low probability of HIT based on the results of the PaGIA and SRA. Overall, the interrater reliability of the scoring system was fair. 
Introduction
Clinicians must be able to promptly decide which patients suspected of having heparin-induced thrombocytopenia (HIT) warrant a change in anticoagulation in order to prevent potential life-threatening thrombosis. Although alternatives to heparin anticoagulation are readily available, they are not always as easy to manage or reverse. Thus, the ability to accurately diagnose or exclude HIT in a timely manner is of utmost importance. For all the patients who had developed HIT, the use of alternate anticoagulant agents, including direct thrombin inhibitors and anti-Xa agents, is preferable. There is an increasing amount of data supporting the use of these alternative agents in a wide variety of clinical circumstances. The use of alternative anticoagulant agents for the treatment of patients with HIT is based on the premise that these agents do not generate or crossreact with anti-heparin platelet factor 4 antibodies (H-PF4; or HIT antibodies), and are effective and well tolerated for the prophylaxis or treatment of thrombosis. Available agents include parenteral direct thrombin inhibitors (as Danaparoid, which is composed of heparan, dermatan, and chondroitin sulfates, has been used extensively in the treatment of patients with HIT in a wide variety of clinical situations [1] ; Fondaparinux, which is a synthetic pentasaccharide that has been extensively studied for use in orthopedic and abdominal surgery prophylaxis, and the treatment of deep venous thrombosis (DVT) and pulmonary embolism) [2] and factor Xa inhibitors.
The diagnosis of HIT relies upon a combination of clinical assessment and laboratory testing. Clinical scoring systems, such as Warkentin's 4T's score (thrombocytopenia, timing, thrombosis, other causes of thrombocytopenia not evident) have been developed to assess the pretest likelihood of HIT [3] and have proven to be very useful [4, 5] . Laboratory testing includes both antigenic and functional assays. The 14C serotonin release assay (SRA) is a functional assay measuring activation of platelets by the pathogenic H-PF4 antibodies [6, 7] . Although demonstrating an excellent sensitivity and specificity for the syndrome of HIT, the availability of this test in our health service is limited to a few specialized laboratories. Consequently, the test often has a prolonged turn around time, limiting its usefulness for serious decision making. Its main utility in our laboratory has been to confirm or refute a previously made suspected diagnosis of HIT.
The Diamed ID H-PF4 (ID-H-PF4) particle gel immunoassay (PaGIA) is a simple and rapid immunoassay that detects H-PF4 antibodies [8] . Despite a rapid result and a high sensitivity, immunoassays in general have a much lower specificity than functional assays [9] , stipulating that only a small proportion of those with a HPF4 antibody develop the full syndrome of HIT [10] . That is particularly in a low likelihood scenario, a patient may have a H-PF4 antibody without it necessarily being the cause of their thrombocytopenia.
In this study we aimed to establish an upfront diagnostic strategy (algorithm) for HIT that would be well tolerated, practical and applicable to the routine management of patients. 4T's score All patients were assigned a 4T's score (Table 1) by the hematologist. It was planned that scoring had to be performed at the time of the referral for HIT testing. This involved reviewing the patient's pathology results with respect to the pattern of the platelet fall, as well as contact with the treating clinician to ascertain the required clinical information.
Patients and methods
Diamed ID heparin platelet factor 4 particle gel immunoassay The ID H-PF4 PaGIA (Diamed AG, Cressier sur Morat, Switzerland) was performed on all samples. The test is based on the ID microtyping particle gel agglutination system, in which red-dyed polymer particles coated with complexes of H-PF4 are prevented from passing through the column when agglutinated by anti-H-PF4 antibodies. Initially, either a plasma or serum sample was accepted for assay, however, later package inserts indicated that serum was required (with no mention of the unsuitability of plasma). Testing was performed on either fresh or frozen samples (stored at À308C for up to 7 days before processing) depending on the clinical urgency for testing. Prior to testing, samples were heat inactivated for 30 min at 568C, centrifuged and processed as per manufacturer's instructions. The heat treatment step was suggested by a local laboratory with more extensive experience of the methodology and conveyed to us by the Australian distributor of the kit. At that time, it was noticed that one of the batches of ID-cards available in the country was difficult to interpret because of streaky agglutination. Heat treatment of the serum or plasma appeared to remove the streakiness. We also found that column agglutination was difficult to interpret on a number of samples with two different patterns of nonspecific agglutination seen. In the first pattern, there was very fine agglutination throughout the column with a majority of the red micro beads collecting at the bottom of the column with no aggregate at the top. In the second pattern, there was a very fine red line at the top of the column with the remainder of the beads passing through the column. This pattern was possibly due to fibrin aggregates in plasma samples. The manufacturer's package insert advice regarding the significance of the result in these scenarios evolved as experience was gained with the assay. The approach of our laboratory to ambiguous results was to repeat the assay and to request a serum sample in cases in which the equivocal test was on a plasma sample. Although these ambiguous patterns were variably reported by our laboratory at the time, all results that were not clearly negative (i.e. all micro beads passing through the column) on repeat testing, were recorded as positive for the purposes of this analysis in an attempt to avoid missing possible cases of HIT. The pattern of any ambiguous reaction was documented in the laboratory workbook of results.
14C Serotonin release assay
The biologic effect of the patient's heparin-induced IgG antibody was determined using the 14C-SRA. In brief, platelets were prepared from healthy individuals by collection of blood into acid-citrate-dextrose solution (1 : 6, vol/vol). Platelet-rich plasma (PRP) was obtained by centrifugation within 10 min at 250 rpm (rotation/min) and room temperature for 15 min. The platelets were washed with calcium and albumin-free Tyrode buffer containing 2 U/ml apyrase (Sigma Aldrich, Deisenhofen, Germany) and 2 mg/ml r-hirudin (Hoechst Marion Roussel, Bad Soden, Germany), pH 6.2, and resuspended in calcium and magnesium containing albumin-free Tyrode buffer, pH 7.4. The platelet count was adjusted to 300 Â 10 3 /ml (300 Â 10 9 /l). The PRP was incubated with 14C-serotonin (Amersham Pharmacia Biotech GmbH, Freiburg, Germany) for 45 min at 378C (10 mCi 14C-serotonin/ml of PRP). Two hundred microliters of serum was incubated at 568C for 30 min and was centrifuged at 1800 g for 20 min at 258C. Twenty microliters of the middle layer, 75 ml of the platelet preparation, and 5 ml of the heparin solution (0.1 and 100 U heparin, final concentration, 160 U/mg dry substances, Braun AG, Melsungen, Germany) were incubated for 1 h and at 258C under gentle mixing. Fifty microliters of a 27 mmol concentration of ethylenediaminetetraacetic acid (Sigma Aldrich) was added to terminate the reaction. Samples were centrifuged within 10 min at 1800 g and room temperature for 20 min, and the radioactivity of 50 ml of the supernatant was measured in a scintillation counter (Beckman Instrument GmbH, Munich, Germany). The maximum release of 14C-serotonin from platelets was obtained after lysis of platelets with 25 ml of Triton X-100 (Sigma Aldrich). A positive result was defined as radioactivity above the 2-fold SD of the negative control.
Heparin-induced thrombocytopenia diagnosis and patient outcomes
The diagnostic utility (i.e. sensitivity, specificity, positive and negative predictive values) of H-PF4 by PaGIA was calculated based upon the result of the SRA. Results from previously published studies have indicated two particular groups of interest; those with a low 4T's score and a positive H-PF4 by PaGIA, and those with a high clinical score and a negative H-PF4 by PaGIA. In order to evaluate the safety of any potential diagnostic strategy, a chart review was also undertaken on these two sets of patients to assess their progress, management and outcomes. After review of records, pathology results and clinical progress including platelet response to cessation/ continuation of heparin, a final clinical diagnosis of HIT was assigned to H-PF4 by PaGIA positive patients as likely, possible or unlikely.
Results
Complete results are available for 50 patients referred for HIT testing in this period. Patient characteristics are shown in Table 2 . The median age was 62 (range 17-97 years). Twenty-five of them received therapeutic dose of heparin (fractioned heparin) (5000 unit of heparin IV infusion followed by 18 unit/kg per h), 10 patients received prophylactic dose (5000 unit per 12 h), 15 patients received enoxaparine (unfractioned low molecular weight heparin) 1 unit/kg twice daily subcutaneously.
The clinical score, H-PF4 by PaGIA and SRA results are shown in Table 3 . Sixteen of the patients (32%) had a low 4T's clinical score, 26 (52%) had an intermediate score, and only eight (16%) had a high score. A positive H-PF4 by PaGIA was seen in seven patients (14%). As might be anticipated, the likelihood of obtaining a positive H-PF4 by PaGIA increased with an increasing clinical score, with positive H-PF4 by PaGIA results in low, intermediate and high scoring patients of 6.25, 7.7 and 50%, respectively. The negative predictive value was 100%. Five (10%) patients in our cohort had a positive SRA. All patients with a positive SRA were included in the intermediate (two of 26 patients, 7.7%) or high (three of eight patients, 37.5%) score groups. Therefore, the negative predictive value of a low 4T's score was 100%, effectively ruling out HIT.
Combining the clinical score and the H-PF 4 by PaGIA results improved the positive predictive value of the PaGIA by effectively increasing the pretest probability of HIT. The positive predictive value of PaGIA in low, intermediate and high score patients was 6.25, 7.7 and 37.5%, respectively. Of particular note, the one of 16 (6.25%) low scoring patients with a positive H-PF4
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One patient with a low 4T's score and a positive H-PF4 by PaGIA were considered unlikely to have HIT on retrospective clinical review. This group largely comprises patients for whom HIT testing was probably inappropriate, including those who showed either a minimal decline in the platelet count, or in cases in which there was exposure to heparin in an inappropriate time frame.
All four patients with a high 4T's score and negative H-PF4 by PaGIA subsequently went on to have a negative SRA. Chart review of these patients demonstrated that none of them were considered to have a likely diagnosis of HIT, although there was one patient with a complicated medical history, in whom the syndrome of HIT was considered initially, but later excluded. An example of how a patient unlikely to have HIT received a high 4T's score was the patient whose platelet count dropped more than 50% (2 points) after 5 days of heparin therapy (2 points) on an extracorporeal membrane oxygen circuit, in whom there was thrombosis within the circuit at day 5 (2 points 
Discussion
This study showed that over half, 52% of the requests were in patients with an intermediate 4T's score, and only 10% of patients were ultimately diagnosed with HIT by SRA. From a clinical practice perspective, it is important to be able to accurately identify this small percentage of patients in order to make a timely change to their anticoagulation, and thus, prevent serious thrombotic complications. However, this is made all the more difficult by the fact that readily available diagnostic tests, such as PaGIA, have relatively low positive predictive values [9] . In our study, the overall positive predictive value of the PaGIA was 92%. Simply changing anticoagulation in all patients with a positive PaGIA may not always be preferable because it may expose the patient to some risk, given the difficulty in reversing some of the alternative agents. Thus, although it is important to identify those with HIT, it is equally important to minimize the number in whom HIT cannot be adequately excluded.
It was very instructive to note that one of the patients with a low 4T's score proceeded to an ultimate diagnosis of HIT as determined by SRA testing. In a previous report, one of 119 low scoring patients (total cohort of 336 patients) was ultimately diagnosed with HIT according to pre-hoc laboratory criteria [4] . The low scoring patient diagnosed with HIT was subsequently shown to have an underlying antiphospholipids antibodyassociated autoimmune disorder and potentially had autoantibodies against HPF4, therefore, possibly representing an atypical case of HIT. In another series, Pouplard et al. [5] , found 0 of 74 low scoring patients (total cohort of 213 patients) were ultimately diagnosed with HIT. In our study, those with a low score and a positive PaGIA were shown not to have HIT by either SRA as a gold standard or as a result of chart review by an expert hematologist. Thus, there is strong evidence that a low 4T's score argues against a diagnosis of HIT. It could be considered that HIT should not be suspected if the 4T's score is low (particularly when there is no thrombosis) and that no further testing is performed in such patients unless there was a compelling reason. Obviously this presupposes that the clinical score is applied correctly (which may not always be the case) and that the patient does not have an atypical form of HIT.
In our series there were no false negative PaGIA results as assessed by SRA results and chart review. This is consistent with previously published findings [5] that demonstrated only one false negative in a series of 213 patients for a negative predictive value of 99.4% (this patient scored high on the 4T's clinical score). Given the excellent sensitivity of the assay, it might be proposed that only those with a positive PaGIA is considered further to be at significant risk of HIT. The finding of a false negative PaGIA in the Pouplard et al. [5] series is a concern, however, and we would, therefore, be worried about the prospect of dismissing HIT in high 4T's score patients in whom the prevalence of the disorder is as high as 37.5% (three of eight patients in our series with a high score had a positive SRA).
In our study we use an alternative anticoagulant for all PaGIA positive patients. Strutt et al. [11] reported eight of 13 intermediate scoring patients and one of five high scoring patients with a positive PaGIA were not commenced on alternative anticoagulation. Although it appears that this may represent suboptimal management, we feel that it is likely to reflect a widely experienced difficulty in managing the often very complicated clinical scenario of potential HIT patients.
Our study demonstrated that all SRA-positive patients were also positive for PaGIA. In contrast, Strutt et al. [11] demonstrated three PaGIA-positive, SRA-negative patients (one high score and two intermediate score) who were possible HIT cases on retrospective clinical and laboratory review, implying a possible false-negative SRA in these patients. In one of these cases, repeat SRA testing was in fact positive. This suggests that the SRA should not be relied upon alone to guide future patient management and that a retrospective critical review of all clinical and laboratory results may be important in patients with a putative initial diagnosis of HIT.
In conclusion, the proposed strategy of a quick, simple algorithm, as described in this report vastly reduces to a manageable number those in whom HIT cannot be adequately excluded. In cases in which the diagnosis still remains in doubt, it is preferable and safer to manage them as possible HIT and alter the anticoagulation. The variable management of potential HIT cases identified in this series illustrates the need for a more systematic approach to this initial diagnosis. This need is likely to be greatest in centres where access to expert hematological advice is not rapidly available.
